181 related articles for article (PubMed ID: 31895563)
1. Discovery of a Small Side Cavity in Sphingosine Kinase 2 that Enhances Inhibitor Potency and Selectivity.
Sibley CD; Morris EA; Kharel Y; Brown AM; Huang T; Bevan DR; Lynch KR; Santos WL
J Med Chem; 2020 Feb; 63(3):1178-1198. PubMed ID: 31895563
[TBL] [Abstract][Full Text] [Related]
2. Lipophilic tail modifications of 2-(hydroxymethyl)pyrrolidine scaffold reveal dual sphingosine kinase 1 and 2 inhibitors.
Li H; Sibley CD; Kharel Y; Huang T; Brown AM; Wonilowicz LG; Bevan DR; Lynch KR; Santos WL
Bioorg Med Chem; 2021 Jan; 30():115941. PubMed ID: 33385956
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors.
Congdon MD; Childress ES; Patwardhan NN; Gumkowski J; Morris EA; Kharel Y; Lynch KR; Santos WL
Bioorg Med Chem Lett; 2015 Nov; 25(21):4956-4960. PubMed ID: 25862200
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Potent and Selective Sphingosine Kinase 1 Inhibitor through the Molecular Combination of Chemotype-Distinct Screening Hits.
Schnute ME; McReynolds MD; Carroll J; Chrencik J; Highkin MK; Iyanar K; Jerome G; Rains JW; Saabye M; Scholten JA; Yates M; Nagiec MM
J Med Chem; 2017 Mar; 60(6):2562-2572. PubMed ID: 28231433
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors.
Patwardhan NN; Morris EA; Kharel Y; Raje MR; Gao M; Tomsig JL; Lynch KR; Santos WL
J Med Chem; 2015 Feb; 58(4):1879-1899. PubMed ID: 25643074
[TBL] [Abstract][Full Text] [Related]
6. Probing the substitution pattern of indole-based scaffold reveals potent and selective sphingosine kinase 2 inhibitors.
Congdon M; Fritzemeier RG; Kharel Y; Brown AM; Serbulea V; Bevan DR; Lynch KR; Santos WL
Eur J Med Chem; 2021 Feb; 212():113121. PubMed ID: 33445156
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate.
Kharel Y; Raje M; Gao M; Gellett AM; Tomsig JL; Lynch KR; Santos WL
Biochem J; 2012 Oct; 447(1):149-57. PubMed ID: 22747486
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.
Kharel Y; Mathews TP; Gellett AM; Tomsig JL; Kennedy PC; Moyer ML; Macdonald TL; Lynch KR
Biochem J; 2011 Dec; 440(3):345-53. PubMed ID: 21848514
[TBL] [Abstract][Full Text] [Related]
9. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors.
Mathews TP; Kennedy AJ; Kharel Y; Kennedy PC; Nicoara O; Sunkara M; Morris AJ; Wamhoff BR; Lynch KR; Macdonald TL
J Med Chem; 2010 Apr; 53(7):2766-78. PubMed ID: 20205392
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.
Schnute ME; McReynolds MD; Kasten T; Yates M; Jerome G; Rains JW; Hall T; Chrencik J; Kraus M; Cronin CN; Saabye M; Highkin MK; Broadus R; Ogawa S; Cukyne K; Zawadzke LE; Peterkin V; Iyanar K; Scholten JA; Wendling J; Fujiwara H; Nemirovskiy O; Wittwer AJ; Nagiec MM
Biochem J; 2012 May; 444(1):79-88. PubMed ID: 22397330
[TBL] [Abstract][Full Text] [Related]
11. Building a better sphingosine kinase-1 inhibitor.
Lynch KR
Biochem J; 2012 May; 444(1):e1-2. PubMed ID: 22533672
[TBL] [Abstract][Full Text] [Related]
12. Drugging sphingosine kinases.
Santos WL; Lynch KR
ACS Chem Biol; 2015 Jan; 10(1):225-33. PubMed ID: 25384187
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase 2 inhibitor SG-12 induces apoptosis via phosphorylation by sphingosine kinase 2.
Hara-Yokoyama M; Terasawa K; Ichinose S; Watanabe A; Podyma-Inoue KA; Akiyoshi K; Igarashi Y; Yanagishita M
Bioorg Med Chem Lett; 2013 Apr; 23(7):2220-4. PubMed ID: 23434415
[TBL] [Abstract][Full Text] [Related]
14. Identification of selective inhibitors of sphingosine kinases 1 and 2 through a structure-activity relationship study of 4-epi-jaspine B.
Ohno H; Honda M; Hamada N; Miyagaki J; Iwata A; Otsuki K; Maruyama T; Nakamura S; Nakanishi I; Inuki S; Fujii N; Oishi S
Bioorg Med Chem; 2017 Jun; 25(12):3046-3052. PubMed ID: 28408190
[TBL] [Abstract][Full Text] [Related]
15. Rational design of SphK inhibitors using crystal structures aided by computer.
Ding T; Zhi Y; Xie W; Yao Q; Liu B
Eur J Med Chem; 2021 Mar; 213():113164. PubMed ID: 33454547
[TBL] [Abstract][Full Text] [Related]
16. Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.
Childress ES; Kharel Y; Brown AM; Bevan DR; Lynch KR; Santos WL
J Med Chem; 2017 May; 60(9):3933-3957. PubMed ID: 28406646
[TBL] [Abstract][Full Text] [Related]
17. In Silico Characterization of Structural Distinctions between Isoforms of Human and Mouse Sphingosine Kinases for Accelerating Drug Discovery.
Worrell BL; Brown AM; Santos WL; Bevan DR
J Chem Inf Model; 2019 May; 59(5):2339-2351. PubMed ID: 30844267
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine kinase inhibitors: a review of patent literature (2006-2015).
Lynch KR; Thorpe SB; Santos WL
Expert Opin Ther Pat; 2016 Dec; 26(12):1409-1416. PubMed ID: 27539678
[TBL] [Abstract][Full Text] [Related]
19. Structural Requirements and Docking Analysis of Amidine-Based Sphingosine Kinase 1 Inhibitors Containing Oxadiazoles.
Houck JD; Dawson TK; Kennedy AJ; Kharel Y; Naimon ND; Field SD; Lynch KR; Macdonald TL
ACS Med Chem Lett; 2016 May; 7(5):487-92. PubMed ID: 27190598
[TBL] [Abstract][Full Text] [Related]
20. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.
Kennedy AJ; Mathews TP; Kharel Y; Field SD; Moyer ML; East JE; Houck JD; Lynch KR; Macdonald TL
J Med Chem; 2011 May; 54(10):3524-48. PubMed ID: 21495716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
